• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS One . Liver injury with COVID-19 based on gastrointestinal symptoms and pneumonia severity

tetano

Editor, Senior Moderator
PLoS One


. 2020 Nov 4;15(11):e0241663.
doi: 10.1371/journal.pone.0241663. eCollection 2020.
Liver injury with COVID-19 based on gastrointestinal symptoms and pneumonia severity


Shun Kaneko[SUP] 1 [/SUP], Masayuki Kurosaki[SUP] 1 [/SUP], Kaoru Nagata[SUP] 2 [/SUP], Reiko Taki[SUP] 3 [/SUP], Ken Ueda[SUP] 2 [/SUP], Satoko Hanada[SUP] 3 [/SUP], Koji Takayama[SUP] 3 [/SUP], Shinichiro Suzaki[SUP] 4 [/SUP], Naoshige Harada[SUP] 4 [/SUP], Toru Sugiyama[SUP] 5 [/SUP], Masayuki Nagasawa[SUP] 6 [/SUP], Namiki Izumi[SUP] 1 [/SUP]



Affiliations

Abstract

Background/aim: The coronavirus disease 2019 (COVID-19) had become a big threat worldwide. Liver injury is not uncommon in patients with COVID-19, and clarifying its characteristics is needed. This study aimed to identify factors associated with liver injury and to develop a new classification of predictive severity in patients with COVID-19.
Methods: Confirmed patients with COVID-19 (n = 60) were recruited retrospectively from Musashino Red Cross Hospital. The factors of liver injury especially on the elevation of liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) were analyzed. Grading was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Results: During a median hospitalization follow-up of 15 (4-41) days, 51 (85.0%) patients had COVID-19 pneumonia. In clinical courses, oxygenation was needed for 25 (41.6%) patients and intubation was needed for 9 (15.0%) patients. A total of 27 (45.0%) patients had gastrointestinal symptoms (GS), such as appetite loss, diarrhea, and nausea. A logistic regression analysis revealed that C-reactive protein (CRP) at baseline, oxygenation, intubation, and GS were significant factors of liver injury. Based on these results, patients were classified into three groups: group 1, no oxygenation pneumonia; group 2, pneumonia with oxygenation or GS; and group 3, intubation. We classified 25 (41.7%), 26 (43.3%), and 9 (15.0%) patients into mild, moderate, and severe groups, respectively. The peak of AST and ALT levels was significantly stratified with this criteria (mild [median AST, 28 IU/L; median ALT, 33 IU/L], moderate [median AST, 48 IU/L; median ALT, 47.5 IU/L], and severe [median AST, 109 IU/L; median ALT, 106 IU/L]; P<0.001 and P = 0.0114, respectively).
Conclusion: COVID-19-related liver injury was significantly stratified based on GS and severity of pneumonia.
 
Back
Top Bottom